Debate: Paclitaxel Plus Carboplatin as Systemic Therapy for Endometrial Cancers: PRO: Systemic Therapy for all Endometrial Cancers should be Paclitaxel Plus Carboplatin

Matthew A. Powell


Clin Ovarian Cancer. 2010;3(1):14-17. 

In This Article


Optimal therapy for patients at an increased risk for recurrence following initial surgical therapy is unknown. Emerging data from several randomized controlled trials would suggest these patients should be treated with both chemotherapy and radiation. The optimal chemotherapeutic regimen is also unknown. The regimens DC or carboplatin/paclitaxel appear to be most appropriate to use as current therapy directed against endometrial carcinoma. The more manageable toxicity profile, especially immediately following radiation therapy, and the added ability of combining further agents in the future make these 2-drug regimens superior. PDC may have a role in the more rare chemotherapy-naive patient whose disease recurs, but as we get better at determining which patients are at high risk for relapse and treat them adjuvantly, this group of patients will likely be small. In short, carboplatin/paclitaxel is the best systemic therapy for endometrial carcinoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: